Navigation Links
Simbionix Increases Product Offerings for OB/GYN Physicians
Date:3/11/2009

CLEVELAND and ZURICH, Switzerland, March 11 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, and VirtaMed, a Swiss medical engineering company, announced today a global collaboration agreement. Simbionix will exclusively distribute, market, and provide service for the VirtaMed HystSim, an advanced virtual reality hysteroscopy simulator.

Simbionix already offers a wide spectrum of simulators for minimal invasive surgery. "This new agreement further expands our product offering," says Simbionix CEO Gary Zamler. "The addition of the HystSim simulator, along with our recently launched laparoscopic surgery module for gynecology, shows how seriously Simbionix is investing in women's healthcare issues".

Simbionix' President and founder, Mr. Ran Bronstein, adds: "Our simulation technology is definitely a revolution in the world of medical training and assessment. We are happy to be working together with VirtaMed, a company as committed to technology and simulation quality as we are. Simbionix will keep increasing its product offering to the medical community and bring quality and service to its customers and partners."

"VirtaMed is thrilled to be working together with Simbionix, the market leader in surgical simulation," adds VirtaMed CEO Stefan Tuchschmid. "Simbionix is a partner that will ensure the HystSim simulator is available globally. We truly appreciate Simbionix' commitment to provide the best possible training for surgeons in every field."

VirtaMed HystSim(TM) will be officially launched at the next ACOG (American College of Obstetricians and Gynecologists) annual clinical meeting held in Chicago on May 2nd.

Further information and product demonstrations are available from your local Simbionix sales representative and at http://www.simbionix.com.

About VirtaMed

VirtaMed is a Swiss based company with an interdisciplinary background in medicine and engineering. The HystSim(TM) system is the first VirtaMed product and provides instructional teaching and training of diagnostic and therapeutic hysteroscopy. VirtaMed's mission is to develop state-of-the-art training tools for endoscopic surgery of highest possible realism, all with the ultimate goal to improve the quality of patient care. Additional company information can be found at http://www.virtamed.com.

About Simbionix

Simbionix is a global leader in medical simulation technology. Simbionix mission is to provide state of the art, computer-assisted metrics-based surgical simulation systems, and set the standard for minimally invasive surgical training and performance.

Simbionix products provide medical experts with hands-on training in a comprehensive array of MIS procedures, including; GI Endoscopy, Endourology, percutaneous access, advanced laparoscopic procedures and Endovascular procedures. Visit http://www.simbionix.com

    Contact:
    Inbal Mazor
    VP Marketing
    Simbionix
    inbal@simbionix.com
    Tel: +972-8-9211177



'/>"/>
SOURCE Simbionix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
2. New Colorectal Module From Simbionix Advances Laparoscopic Cancer Treatment
3. William E. Lewandowski to Lead Simbionix US Marketing Team in Simbionixs Strategic Expansion in the US Market
4. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
5. Simbionix Launches Innovative Patient-Specific Simulation
6. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
7. Simbionix Takes Non-Invasive GYN Surgical Training to the Next Level
8. 2007 a "Record Year" for Successful Validation Studies of Simbionix Simulators
9. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
10. Despite Economic Woes, Physician Compensation Increases
11. Gerresheimer Substantially Increases Quarterly Operating Profit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... Louisville, KY and San Diego, CA (PRWEB) , ... April 29, ... ... the National Stem Cell Foundation (NSCF) to support the development of a patient-specific stem ... by Dr. Andrés Bratt-Leal in the lab of Dr. Jeanne Loring at The Scripps ...
(Date:4/29/2016)... TURIN, Italy , April 29, 2016 ... version 5.11, the latest update to its industry-leading treatment ... has shown that Monaco version ... Users can now attain calculation speeds up to four ... Monaco . With the industry,s gold standard ...
(Date:4/28/2016)... 2016 Q BioMed Inc. ... CEO  was featured in an article he wrote ... Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... is an essential business journal for life science ... to Big Pharmas. Their content is designed to ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):